Digital Cognitive Assessment Market (2026-2036)

The growth of this market is mainly driven by a Medicare coverage requirement that obliges clinicians to detect cognitive impairment at the annual wellness visit without specifying how, by a dementia care payment model that pays a monthly amount per patient and makes comprehensive assessment a condition of participation rather than a separately billed test, by the arrival of blood-based biomarkers that need a preceding step to decide who should be tested, and by a regulatory pathway that now holds four separate class II shelves for software of this kind, which allows a vendor to sell a screening aid, a concussion aid or a prognostic tool under distinct claims. Cognitive testing has historically been paid for as professional time rather than as a product, so the share of total spending that reaches a software vendor is small relative to the number of assessments performed, and the growth rate reflects a transfer of that spending toward licensed software more than an increase in the number of people assessed.

However, factors such as the absence of any recommendation to screen for cognitive impairment, the lack of a quality measure obliging a health system to assess a defined population, reimbursement that sits inside visit codes and bundled payments rather than in a code that pays for the test, and purchasing decisions taken practice by practice on an internal efficiency case are expected to restrain the growth of this market to some extent. Because the task force could not determine the balance of benefits and harms, no quality measure obliges a health system to screen, and a vendor competes for a share of a payment already made rather than for new money, which produces long sales cycles and small initial order sizes.

42 CFR 410.15, which lists among the elements of personalized prevention plan services furnished at the Medicare annual wellness visit the "Detection of any cognitive impairment that the individual may have" and names no particular instrument for carrying it out establishes the demand base for this market. The regulation defines detection as assessing cognitive function by direct observation together with consideration of patient reports and concerns raised by family members, friends, caretakers or others, and it leaves the choice of method to the clinician. Alongside that requirement sits the U.S. Preventive Services Task Force recommendation on screening for cognitive impairment in older adults, dated 25 February 2020 and currently under update, which is an I statement concluding that the evidence is insufficient to assess the balance of benefits and harms of screening community-dwelling adults aged 65 years and older who have no recognised signs or symptoms of cognitive impairment. The practical consequence is a market created by an administrative obligation rather than by a clinical recommendation, which shapes how products are bought: a clinician who must record detection but has no instrument named for the purpose will choose the method that consumes the fewest minutes of a visit that also has to cover height, weight, blood pressure, medical and family history, depression risk, functional ability and safety, a written screening schedule for the next five to ten years, personalized health advice, advance care planning at the discretion of the patient, a review of current opioid prescriptions and screening for substance use disorder risk. A digital test that runs unsupervised on a tablet in the waiting room competes against a two-minute conversation, not against formal neuropsychological testing.

Spending moves to a different payer and a different clinician once impairment is detected. CPT 99483 pays for a cognitive assessment and care plan that carries the elements of a level five evaluation and management visit, requires an independent historian to be present, and is associated with roughly sixty minutes of face-to-face time, with add-on code G2212 available beyond that hour. The service covers a cognitive-focused examination, a review of history and records, a functional assessment of activities of daily living including decision-making capacity, a high-risk medication review, neuropsychiatric screening including depression and anxiety, evaluation of home and driving safety, review of social supports, and advance care and palliative care planning, and it closes with a written plan addressing neuropsychiatric and neurocognitive symptoms, functional limitations and referrals to community resources. Staging tools such as the Functional Assessment Staging Test and the Clinical Dementia Rating appear among the elements of that service. A product sold into the annual wellness visit is therefore sold on brevity and a product sold into the care planning visit is sold on documentation depth, and the two rarely come from the same purchase decision.

the Guiding an Improved Dementia Experience model operated by the Centers for Medicare & Medicaid Services, a voluntary national model that started on 1 July 2024 and runs for eight years changes the unit of sale again. Participating providers and suppliers enrolled in Medicare Part B, excluding durable medical equipment and laboratory suppliers, receive a dementia care management payment set as a per-patient per-month amount and billed through twelve G-codes, with one such payment per patient per calendar month. Base rates vary by model tier and are adjusted for population and income, for performance and for geographic cost differences, and a base rate can reach 1.75 times its starting level once all adjustments are applied. Respite services are billed separately under codes G0529 to G0531 for in-home, adult day and facility-based care, available to patients who have an unpaid primary caregiver and fall into moderate to high-complexity dyad tiers, subject to an annual cap of USD 2,625 per patient for performance year 2026. Coinsurance and deductibles are waived for these services. Participation requires an interdisciplinary team that includes a care navigator and a dementia-proficient clinician able to bill Part B evaluation and management services, and it requires comprehensive assessment, care planning, home visits, ongoing monitoring, 24/7 caregiver access, care coordination, transitional care, referrals to community-based services, medication management and caregiver education and support. Assessment inside that structure is a cost the participant absorbs out of a fixed monthly payment, which rewards software that shortens a repeated longitudinal measurement rather than software priced per test.

21 CFR 882.1470, the class II classification for a computerized cognitive assessment aid, product code PKQ covers the general screening aid, with an exempt variant under product code PTY and a concussion-specific classification under 21 CFR 882.1471, product code POM. 21 CFR 882.1454, the class II classification for prognostic assessment software of mild cognitive impairment, product code QWT, defined as prescription software that combines information from multiple clinical data sources to estimate the likelihood that a patient with mild cognitive impairment progresses to more severe impairment or dementia within a defined period and intended for adjunctive use rather than as a stand-alone tool sits apart from all three. A vendor can therefore market the same measurement engine as an aid that supports a clinician in detecting impairment, or as software that estimates progression risk, and the second claim carries a different evidentiary burden and reaches a different buyer. The prognostic classification is the commercially significant one for the next several years because it is the claim that a specialist referral pathway needs.

A plasma test that indicates amyloid pathology is informative in a population with objectively measured impairment and loses specificity of meaning in a population presenting only subjective complaint, so the test that decides who proceeds to a biomarker determines the positive predictive value of the pathway as a whole. Cognitive assessment consequently moves from a documentation task performed to satisfy a coverage element into a triage function with downstream cost consequences, and that shift is what allows a vendor to price software against the cost of an avoided biomarker test or an avoided specialist referral rather than against the cost of a paper form.

Clinical trial cognitive assessment has been a professional service business for two decades, delivered with trained raters, central review and validated batteries, and it is consolidated among a small number of providers with regulatory submission experience. Clinical practice assessment is supplied by specialist software firms, most of them privately held or listed on growth markets, and by test publishers converting established paper instruments into digital administration. Speech and language analysis, drawing and graphomotor analysis, eye tracking and motor measurement have entered through acquisition rather than through independent scale, which has placed digital biomarker capability inside firms whose core business is batteries or trial services.